Tocqueville Asset Management L.P. Purchases Shares of 29,725 Voyager Therapeutics Inc (VYGR)
Tocqueville Asset Management L.P. purchased a new stake in Voyager Therapeutics Inc (NASDAQ:VYGR) during the fourth quarter, according to the company in its most recent filing with the SEC. The firm purchased 29,725 shares of the company’s stock, valued at approximately $493,000.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Thompson Davis & CO. Inc. boosted its holdings in shares of Voyager Therapeutics by 67.7% in the 4th quarter. Thompson Davis & CO. Inc. now owns 7,485 shares of the company’s stock valued at $124,000 after purchasing an additional 3,021 shares during the last quarter. JPMorgan Chase & Co. acquired a new position in shares of Voyager Therapeutics in the 3rd quarter valued at $270,000. Bailard Inc. acquired a new position in shares of Voyager Therapeutics in the 4th quarter valued at $232,000. Goldman Sachs Group Inc. boosted its holdings in shares of Voyager Therapeutics by 8.9% in the 2nd quarter. Goldman Sachs Group Inc. now owns 17,048 shares of the company’s stock valued at $153,000 after purchasing an additional 1,399 shares during the last quarter. Finally, Nationwide Fund Advisors lifted its holdings in shares of Voyager Therapeutics by 81.5% during the 3rd quarter. Nationwide Fund Advisors now owns 19,779 shares of the company’s stock valued at $407,000 after acquiring an additional 8,884 shares in the last quarter. Institutional investors own 80.03% of the company’s stock.
In related news, insider Bernard Ravina sold 3,630 shares of Voyager Therapeutics stock in a transaction on Wednesday, January 10th. The shares were sold at an average price of $16.40, for a total transaction of $59,532.00. Following the sale, the insider now owns 7,353 shares of the company’s stock, valued at approximately $120,589.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Dinah Ph.D. Sah sold 15,623 shares of Voyager Therapeutics stock in a transaction on Tuesday, February 27th. The stock was sold at an average price of $30.00, for a total transaction of $468,690.00. Following the sale, the insider now directly owns 140,872 shares in the company, valued at approximately $4,226,160. The disclosure for this sale can be found here. Insiders have sold a total of 21,704 shares of company stock worth $572,928 in the last ninety days. 8.00% of the stock is currently owned by insiders.
Voyager Therapeutics Inc (VYGR) opened at $24.26 on Wednesday. The firm has a market cap of $590.34 and a price-to-earnings ratio of -8.54. Voyager Therapeutics Inc has a 1-year low of $8.10 and a 1-year high of $31.91.
ILLEGAL ACTIVITY NOTICE: “Tocqueville Asset Management L.P. Purchases Shares of 29,725 Voyager Therapeutics Inc (VYGR)” was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this story on another site, it was illegally stolen and reposted in violation of international copyright and trademark legislation. The original version of this story can be viewed at https://www.thecerbatgem.com/2018/03/14/tocqueville-asset-management-l-p-purchases-shares-of-29725-voyager-therapeutics-inc-vygr.html.
About Voyager Therapeutics
Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain.
Want to see what other hedge funds are holding VYGR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Voyager Therapeutics Inc (NASDAQ:VYGR).
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.